PRAX Praxis Precision Medicines

Praxis Precision Medicines to Participate in September Investor Conferences

Praxis Precision Medicines to Participate in September Investor Conferences

BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that Praxis’ management will be attending and presenting in three upcoming investor conferences:

  • Baird 2025 Global Healthcare Conference: a corporate presentation will take place on Tuesday, September 9th at 9:00-9:35am EDT at the InterContinental New York Barclay.
  • H.C. Wainwright 27th Annual Global Investment Conference: a fireside chat will be held on Wednesday, September 10th at 8:30am EDT at the Lotte New York Palace Hotel in New York City. A live webcast of the fireside chat will be available through this .
  • TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit: a corporate presentation will take place virtually on Thursday, September 18th at 3:00-3:30pm EDT.

The Company will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

A replay of the webcasted event will also be available through the “” page under the “” section of the company’s website for 90 days.

About Praxis  

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit  and follow us on , ,  and .



Investor Contact: 
Praxis Precision Medicines 
  
857-702-9452 
 
Media Contact:
Dan Ferry
Life Science Advisors
 
617-430-7576
EN
04/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Praxis Precision Medicines

 PRESS RELEASE

Praxis Precision Medicines to Participate in September Investor Confer...

Praxis Precision Medicines to Participate in September Investor Conferences BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that Praxis’ management will be attending and presenting in three upcoming investor conferences: Baird 2025 Global Healthcare Conference: a corporate presentation will take place on Tuesday, September 9th at 9:00-9:35am E...

 PRESS RELEASE

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nas...

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on September 2, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 6,238 shares of its common stock to...

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
 PRESS RELEASE

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Praxis Precision Medicines to Participate in Upcoming Fireside Chat BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Ritu Baral, Biotechnology Analyst, TD Cowen on September 2, 2025 at 10:00amEST to discuss content shared by Praxis at the 36th International Epilepsy Consortium...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch